US EditionPublished • loading... • Updated
The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
Summary by americanbankingnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at The Goldman Sachs Group in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. They currently have a $41.00 target price on the stock, down from their previous target price of $63.00. […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
